Does Ruxolitinib Really Prolong Survival in Individuals with Myelofibrosis? The Never-ending Story

Overview

Journal Blood Adv

Specialty Hematology

Date 2022 Mar 3

PMID 35240682

Authors

Giovanni Barosi

Robert Peter Gale

Affiliations

Soon will be listed here.

Citing Articles

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis.

Gale R, Barosi G Haematologica. 2024; 109(11):3469-3470.

PMID: 38988273 PMC: 11532677. DOI: 10.3324/haematol.2024.285972.

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.

Verma T, Papadantonakis N, Peker Barclift D, Zhang L Cancers (Basel). 2024; 16(3).

PMID: 38339265 PMC: 10854658. DOI: 10.3390/cancers16030514.

Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.

Maze D, Arcasoy M, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S Bone Marrow Transplant. 2023; 59(2):196-202.

PMID: 37938736 PMC: 10849956. DOI: 10.1038/s41409-023-02146-6.

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.

Tefferi A, Alkhateeb H, Gangat N Blood Cancer J. 2023; 13(1):108.

PMID: 37460550 PMC: 10352315. DOI: 10.1038/s41408-023-00878-8.

SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.

Chifotides H, Masarova L, Verstovsek S Clin Lymphoma Myeloma Leuk. 2023; 23(4):219-231.

PMID: 36797153 PMC: 10378306. DOI: 10.1016/j.clml.2022.12.014.

References

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

Cervantes F, Vannucchi A, Kiladjian J, Al-Ali H, Sirulnik A, Stalbovskaya V . Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013; 122(25):4047-53. DOI: 10.1182/blood-2013-02-485888. View

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

Barosi G, Zhang M, Peter Gale R . Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?. Leukemia. 2014; 28(11):2267-70. DOI: 10.1038/leu.2014.220. View

Verstovsek S, Mesa R, Gotlib J, Levy R, Gupta V, Dipersio J . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807. PMC: 4822164. DOI: 10.1056/NEJMoa1110557. View

Tefferi A, Litzow M, Pardanani A . Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011; 365(15):1455-7. DOI: 10.1056/NEJMc1109555. View

Tefferi A, Barraco D, Lasho T, Shah S, Begna K, Al-Kali A . Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018; 8(3):29. PMC: 5841331. DOI: 10.1038/s41408-018-0067-6. View

Marti-Carvajal A, Anand V, Sola I . Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. Cochrane Database Syst Rev. 2015; (4):CD010298. PMC: 10875410. DOI: 10.1002/14651858.CD010298.pub2. View

Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B . Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Adv. 2021; 6(2):373-375. PMC: 8791590. DOI: 10.1182/bloodadvances.2021006006. View

10.

Thomas J, Jamy O, Shah M, Vachhani P, Go R, Goyal G . Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval. Leuk Res. 2021; 112:106770. DOI: 10.1016/j.leukres.2021.106770. View

11.

Cervantes F, Pereira A . Does ruxolitinib prolong the survival of patients with myelofibrosis?. Blood. 2016; 129(7):832-837. DOI: 10.1182/blood-2016-11-731604. View

12.

Verstovsek S, Kantarjian H, Estrov Z, Cortes J, Thomas D, Kadia T . Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012; 120(6):1202-9. PMC: 4081158. DOI: 10.1182/blood-2012-02-414631. View

13.

Passamonti F, Maffioli M, Cervantes F, Vannucchi A, Morra E, Barbui T . Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014; 123(12):1833-5. DOI: 10.1182/blood-2013-12-544411. View

14.

Barosi G, Rosti V, Gale R . Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. Onco Targets Ther. 2015; 8:1091-102. PMC: 4445786. DOI: 10.2147/OTT.S31916. View

15.

. Patients' preferences within randomised trials: systematic review and patient level meta-analysis. BMJ. 2008; 337:a1864. PMC: 2659956. DOI: 10.1136/bmj.a1864. View

16.

Passamonti F, Cervantes F, Vannucchi A, Morra E, Rumi E, Pereira A . A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2009; 115(9):1703-8. DOI: 10.1182/blood-2009-09-245837. View

17.

Del Paggio J, Berry J, Hopman W, Eisenhauer E, Prasad V, Gyawali B . Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncol. 2021; 7(5):728-734. PMC: 7995135. DOI: 10.1001/jamaoncol.2021.0379. View

18.

Verstovsek S, Mesa R, Gotlib J, Levy R, Gupta V, Dipersio J . Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013; 98(12):1865-71. PMC: 3856961. DOI: 10.3324/haematol.2013.092155. View